TipRanks
BioMarin Pharmaceutical (DE:BM8)
FRANKFURT:BM8
Germany Market
BM8
BioMarin Pharmaceutical
RESEARCH TOOLSreports

BioMarin Pharmaceutical (BM8) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

BM8 Analyst Ratings

Strong Buy
22Ratings
Strong Buy
17 Buy
5 Hold
0 Sell
Based on 22 analysts giving stock ratings to
BioMarin
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BM8 Stock 12 Month Forecast

Average Price Target

€82.18
▲(48.17% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is €82.18 with a high forecast of €109.39 and a low forecast of €52.93. The average price target represents a 48.17% change from the last price of €55.46.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"€43","110":"€110","59.75":"€59.8","76.5":"€76.5","93.25":"€93.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":109.3927814,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€109.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.17691602750001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€82.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.931991,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€52.93</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,59.75,76.5,93.25,110],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.98,57.31944472307692,61.65888944615384,65.99833416923077,70.3377788923077,74.67722361538462,79.01666833846154,83.35611306153847,87.69555778461539,92.03500250769231,96.37444723076923,100.71389195384616,105.0533366769231,{"y":109.3927814,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.98,55.2259166175,57.471833235,59.7177498525,61.96366647,64.20958308750001,66.45549970500001,68.70141632250001,70.94733294000001,73.19324955750001,75.43916617500001,77.68508279250001,79.93099941000001,{"y":82.17691602750001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,52.98,52.976307,52.972614,52.968920999999995,52.965227999999996,52.961535,52.957842,52.954148999999994,52.950455999999996,52.946763,52.94307,52.93937699999999,52.935683999999995,{"y":52.931991,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.71,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.92,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.32,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.78,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.06,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.98,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€109.39Average Price Target€82.18Lowest Price Target€52.93
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on DE:BM8
Jessica Fye
J.P. Morgan
J.P. Morgan
€75.87
Buy
36.80%
Upside
Reiterated
09/21/26
Analysts Conflicted on These Healthcare Names: Tilray (NASDAQ: TLRY) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Guggenheim Analyst forecast on DE:BM8
Debjit Chattopadhyay
Guggenheim
Guggenheim
€75.87
Buy
36.80%
Upside
Reiterated
09/17/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)
Morgan Stanley Analyst forecast on DE:BM8
Sean Laaman
Morgan Stanley
Morgan Stanley
€109.39
Buy
97.25%
Upside
Assigned
09/16/26
Morgan Stanley Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
BMO Capital Analyst forecast on DE:BM8
David Lebowitz
BMO Capital
BMO Capital
€86.46→€85.57
Buy
54.30%
Upside
Assigned
09/16/26
BioMarin price target lowered to $97 from $98 at BMO CapitalBioMarin price target lowered to $97 from $98 at BMO Capital
Citi Analyst forecast on DE:BM8
Eric Joseph
Citi
Citi
―
Buy
―
Reiterated
09/14/26
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), BioMarin Pharmaceutical (BMRN)
Wells Fargo Analyst forecast on DE:BM8
Mohit Bansal
Wells Fargo
Wells Fargo
€70.58
Buy
27.26%
Upside
Reiterated
09/11/26
Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and BioMarin Pharmaceutical (NASDAQ: BMRN)
H.C. Wainwright Analyst forecast on DE:BM8
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
€52.93
Hold
-4.56%
Downside
Reiterated
09/10/26
BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged
Piper Sandler Analyst forecast on DE:BM8
Allison Bratzel
Piper Sandler
Piper Sandler
€77.63→€79.4
Buy
43.16%
Upside
Reiterated
09/01/26
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), BioMarin Pharmaceutical (NASDAQ: BMRN) and Envista Holdings (NYSE: NVST)
Cantor Fitzgerald Analyst forecast on DE:BM8
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
€74.99→€75.87
Buy
36.80%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Karyopharm Therapeutics (NASDAQ: KPTI)
Jefferies Analyst forecast on DE:BM8
Akash Tewari
Jefferies
Jefferies
€91.75→€92.63
Buy
67.02%
Upside
Reiterated
08/31/26
Analyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105
Canaccord Genuity Analyst forecast on DE:BM8
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€100.57
Buy
81.34%
Upside
Reiterated
08/31/26
BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target
William Blair Analyst forecast on DE:BM8
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
08/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and BridgeBio Pharma (NASDAQ: BBIO)
Goldman Sachs Analyst forecast on DE:BM8
Salveen Richter
Goldman Sachs
Goldman Sachs
€61.75
Hold
11.35%
Upside
Reiterated
08/31/26
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
Stifel Nicolaus Analyst forecast on DE:BM8
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€61.75
Hold
11.35%
Upside
Reiterated
08/31/26
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Ionis Pharmaceuticals (NASDAQ: IONS)
TD Cowen Analyst forecast on DE:BM8
Phil Nadeau
TD Cowen
TD Cowen
€105.86
Buy
90.88%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on DE:BM8
Jessica Fye
J.P. Morgan
J.P. Morgan
€75.87
Buy
36.80%
Upside
Reiterated
09/21/26
Analysts Conflicted on These Healthcare Names: Tilray (NASDAQ: TLRY) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Guggenheim Analyst forecast on DE:BM8
Debjit Chattopadhyay
Guggenheim
Guggenheim
€75.87
Buy
36.80%
Upside
Reiterated
09/17/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), BioMarin Pharmaceutical (NASDAQ: BMRN) and Axsome Therapeutics (NASDAQ: AXSM)
Morgan Stanley Analyst forecast on DE:BM8
Sean Laaman
Morgan Stanley
Morgan Stanley
€109.39
Buy
97.25%
Upside
Assigned
09/16/26
Morgan Stanley Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
BMO Capital Analyst forecast on DE:BM8
David Lebowitz
BMO Capital
BMO Capital
€86.46→€85.57
Buy
54.30%
Upside
Assigned
09/16/26
BioMarin price target lowered to $97 from $98 at BMO CapitalBioMarin price target lowered to $97 from $98 at BMO Capital
Citi Analyst forecast on DE:BM8
Eric Joseph
Citi
Citi
―
Buy
―
Reiterated
09/14/26
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), BioMarin Pharmaceutical (BMRN)
Wells Fargo Analyst forecast on DE:BM8
Mohit Bansal
Wells Fargo
Wells Fargo
€70.58
Buy
27.26%
Upside
Reiterated
09/11/26
Analysts Offer Insights on Healthcare Companies: AxoGen (NASDAQ: AXGN) and BioMarin Pharmaceutical (NASDAQ: BMRN)
H.C. Wainwright Analyst forecast on DE:BM8
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
€52.93
Hold
-4.56%
Downside
Reiterated
09/10/26
BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged
Piper Sandler Analyst forecast on DE:BM8
Allison Bratzel
Piper Sandler
Piper Sandler
€77.63→€79.4
Buy
43.16%
Upside
Reiterated
09/01/26
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (NASDAQ: AXSM), BioMarin Pharmaceutical (NASDAQ: BMRN) and Envista Holdings (NYSE: NVST)
Cantor Fitzgerald Analyst forecast on DE:BM8
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
€74.99→€75.87
Buy
36.80%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Karyopharm Therapeutics (NASDAQ: KPTI)
Jefferies Analyst forecast on DE:BM8
Akash Tewari
Jefferies
Jefferies
€91.75→€92.63
Buy
67.02%
Upside
Reiterated
08/31/26
Analyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105
Canaccord Genuity Analyst forecast on DE:BM8
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€100.57
Buy
81.34%
Upside
Reiterated
08/31/26
BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target
William Blair Analyst forecast on DE:BM8
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
08/31/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and BridgeBio Pharma (NASDAQ: BBIO)
Goldman Sachs Analyst forecast on DE:BM8
Salveen Richter
Goldman Sachs
Goldman Sachs
€61.75
Hold
11.35%
Upside
Reiterated
08/31/26
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
Stifel Nicolaus Analyst forecast on DE:BM8
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€61.75
Hold
11.35%
Upside
Reiterated
08/31/26
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), BioMarin Pharmaceutical (NASDAQ: BMRN) and Ionis Pharmaceuticals (NASDAQ: IONS)
TD Cowen Analyst forecast on DE:BM8
Phil Nadeau
TD Cowen
TD Cowen
€105.86
Buy
90.88%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
WSTWest Pharmaceutical Services
OMCLOmnicell
ACHVAchieve Life Sciences
LFMDLifeMD
OVIDOvid Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months
Christopher RaymondRaymond James
Success Rate
15/36 ratings generated profit
42%
Average Return
-0.27%
Copying Christopher Raymond's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -0.27% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
20/43 ratings generated profit
47%
Average Return
-3.69%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 46.51% of your transactions generating a profit, with an average return of -3.69% per trade.
2 Years
Phil NadeauTD Cowen
Success Rate
12/26 ratings generated profit
46%
Average Return
-4.15%
Copying Phil Nadeau's trades and holding each position for 2 Years would result in 46.15% of your transactions generating a profit, with an average return of -4.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BM8 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
26
25
16
17
15
Buy
6
7
10
17
16
Hold
10
13
14
15
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
45
40
49
42
In the current month, BM8 has received 31 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. BM8 average Analyst price target in the past 3 months is 82.18.
Each month's total comprises the sum of three months' worth of ratings.

BM8 Financial Forecast

BM8 Earnings Forecast

Next quarter’s earnings estimate for BM8 is €1.18 with a range of €1.08 to €1.31. The previous quarter’s EPS was €1.07. BM8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BM8 has Performed in-line its overall industry.
Next quarter’s earnings estimate for BM8 is €1.18 with a range of €1.08 to €1.31. The previous quarter’s EPS was €1.07. BM8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BM8 has Performed in-line its overall industry.

BM8 Sales Forecast

Next quarter’s sales forecast for BM8 is €908.30M with a range of €881.84M to €931.67M. The previous quarter’s sales results were €884.94M. BM8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BM8 has Performed in-line its overall industry.
Next quarter’s sales forecast for BM8 is €908.30M with a range of €881.84M to €931.67M. The previous quarter’s sales results were €884.94M. BM8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BM8 has Performed in-line its overall industry.

BM8 Stock Forecast FAQ

What is DE:BM8’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 82.18.
    What is DE:BM8’s upside potential, based on the analysts’ average price target?
    BioMarin Pharmaceutical has 48.17% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BioMarin Pharmaceutical a Buy, Sell or Hold?
          BioMarin Pharmaceutical has a consensus rating of Strong Buy, which is based on 17 buy ratings, 5 hold ratings and 0 sell ratings.
            What is BioMarin Pharmaceutical’s share price target?
            The average share price target for BioMarin Pharmaceutical is 82.18. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €109.39 ,and the lowest forecast is €52.93. The average share price target represents 48.17% Increase from the current price of €55.46.
              What do analysts say about BioMarin Pharmaceutical?
              BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of BioMarin Pharmaceutical?
                To buy shares of DE:BM8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.